Stock-Based Compensation for Novo Nordisk (NVO)
Stock-Based Compensation for Novo Nordisk (NVO): headline value $0 · YoY -100.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
NVO
Currently viewingStock-Based CompensationSwitch metric
Latest period
$0
YoY change
-100.0%
5Y CAGR
-100.0%
Peak year (2024)
$2.29B
Latest annual
$0
Stock-Based Compensation history chart for Novo Nordisk (NVO) from 1990 to 2025
Stock-Based Compensation history table for Novo Nordisk (NVO) from 1990 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $0 | -100.0% | ||
| 2024 | $2.29B | +6.5% | ||
| 2023 | $2.15B | +39.6% | ||
| 2022 | $1.54B | +48.0% | ||
| 2021 | $1.04B | +26.4% | ||
| 2020 | $823.00M | +126.7% | ||
| 2019 | $363.00M | -12.3% | ||
| 2018 | $414.00M | +41.8% | ||
| 2017 | $292.00M | -20.7% | ||
| 2016 | $368.00M | -16.7% | ||
| 2015 | $442.00M | +19.1% | ||
| 2014 | $371.00M | -9.3% | ||
| 2013 | $409.00M | +32.8% | ||
| 2012 | $308.00M | — | ||
| 2011 | $0 | — | ||
| 2010 | $0 | — | ||
| 2009 | $0 | — | ||
| 2008 | $0 | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — | ||
| 1990 | $0 | — |
Stock-Based Compensation values are taken from Novo Nordisk's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in DKK as filed.
Analysis
2025's annual stock-based compensation for Novo Nordisk (NVO) came in at $0 – plunged 100.0% year-over-year.
Over 2020–2025 (5 years), Novo Nordisk stock-based compensation expanded at a -100.0% compound annual rate, with a net decline across the window.
The dataset's maximum stock-based compensation sits at $2.29B (2024); the minimum reading of $0 dates to 1990.
Among 8 Healthcare peers, Novo Nordisk (NVO) ranks 5th; the peer median for stock-based compensation is $313.00M.
Novo Nordisk Stock-Based Compensation by Year
Novo Nordisk Stock-Based Compensation 2025: $0
Novo Nordisk stock-based compensation in 2025 was $0, plunged 100.0% below 2024.
Novo Nordisk Stock-Based Compensation 2024: $2.29B
Novo Nordisk stock-based compensation in 2024 was $2.29B, grew 6.5% from 2023. This figure represents the highest annual value in the available history.
Novo Nordisk Stock-Based Compensation 2023: $2.15B
Novo Nordisk stock-based compensation in 2023 was $2.15B, surged 39.6% from 2022.
Novo Nordisk Stock-Based Compensation 2022: $1.54B
Novo Nordisk stock-based compensation in 2022 was $1.54B, surged 48.0% from 2021.
Novo Nordisk Stock-Based Compensation 2021: $1.04B
Novo Nordisk stock-based compensation in 2021 was $1.04B.
See more financial history for Novo Nordisk (NVO).
Sector peers — Stock-Based Compensation
Companies in the same sector as Novo Nordisk, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $0 | Healthcare |
Frequently asked questions
What is Novo Nordisk's stock-based compensation?
Latest reported stock-based compensation for Novo Nordisk (NVO) is $0 (period ending December 31, 2025).
How has Novo Nordisk stock-based compensation changed year-over-year?
Novo Nordisk (NVO) stock-based compensation changed -100.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Novo Nordisk stock-based compensation?
Novo Nordisk (NVO) stock-based compensation compound annual growth rate is -100.0% over the most recent 5 years available.
When did Novo Nordisk stock-based compensation hit its highest annual value?
Novo Nordisk stock-based compensation reached its highest annual value of $2.29B in 2024.
What was Novo Nordisk stock-based compensation in 2024?
Novo Nordisk (NVO) stock-based compensation in 2024 was $2.29B.
What was Novo Nordisk stock-based compensation in 2025?
Novo Nordisk (NVO) stock-based compensation in 2025 was $0.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
NVO Overview
Company profile, financial tools, and key metrics
NVO Revenue Counter
Earns 9,800 DKK every second. See per minute, hour, and day.
NVO Earnings Counter
Earns 3,248 DKK per second net profit. See per minute, hour, and day.
NVO Economic Scale
Exceeds Cambodia's GDP. Compare with world economies.
NVO What If Invested
What if you had invested $1,000? See historical returns from any date.
NVO How It Makes Money
Discover visual breakdown of 309.06B DKK in revenue — where it comes from and where it goes.
NVO Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
NVO Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
NVO Daily Price Character
Balanced · 47.3% historical win rate (green days). Streaks & record days.
NVO Buybacks
0.10% TTM buyback yield. Shareholder yield & SBC comparison.
NVO Stock Split History
5 splits on record. Dates, ratios, and cumulative multiple.
NVO Dividend Profile
Yield: 4.62%. Safety: 5/8. See full history.
NVO Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
NVO Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.